Keld Danø
#120,782
Most Influential Person Now
Keld Danø's AcademicInfluence.com Rankings
Keld Danøbiology Degrees
Biology
#7313
World Rank
#10214
Historical Rank
Molecular Biology
#833
World Rank
#854
Historical Rank
Biochemistry
#1004
World Rank
#1117
Historical Rank
Download Badge
Chemistry Biology
Keld Danø's Degrees
- PhD Biochemistry University of Copenhagen
- Masters Chemistry University of Copenhagen
Why Is Keld Danø Influential?
(Suggest an Edit or Addition)Keld Danø's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Plasminogen activators, tissue degradation, and cancer. (1985) (2557)
- Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. (1973) (742)
- Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors (1987) (608)
- Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. (1990) (604)
- Impaired wound healing in mice with a disrupted plasminogen gene (1996) (578)
- Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. (1991) (552)
- Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. (2010) (549)
- Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. (1991) (491)
- Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. (1991) (467)
- High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. (1993) (431)
- Plasminogen activation and cancer (2005) (430)
- Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. (1995) (420)
- Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. (1998) (379)
- Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. (1992) (358)
- The Plasminogen Activator Inhibitor PAI-1 Controls In Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin: Implications for Antiangiogenic Strategies (2001) (337)
- cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. (1986) (334)
- Fibrinolysis associated with oncogenic transformation. Partial purification and characterization of the cell factor, a plasminogen activator. (1974) (334)
- Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. (1994) (322)
- Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. (1993) (308)
- The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion (1995) (307)
- The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. (1994) (305)
- Ultrastructural localization of plasma membrane-associated urokinase- type plasminogen activator at focal contacts (1988) (298)
- Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants (1989) (297)
- Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. (1999) (296)
- Functional overlap between two classes of matrix‐degrading proteases in wound healing (1999) (296)
- Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. (1996) (274)
- The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. (1990) (265)
- Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells (1987) (264)
- Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. (1992) (257)
- Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. (1982) (251)
- Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. (1988) (250)
- Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. (1990) (248)
- A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. (1988) (247)
- Plasminogen activation by receptor-bound urokinase. (1991) (245)
- The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. (1991) (243)
- One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. (1988) (231)
- The Receptor for Urokinase-type Plasminogen Activator Is Not Essential for Mouse Development or Fertility (*) (1995) (223)
- Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. (1986) (218)
- Transforming growth factor‐beta is a strong and fast acting positive regulator of the level of type‐1 plasminogen activator inhibitor mRNA in WI‐38 human lung fibroblasts. (1987) (211)
- Plasminogen activator inhibitor type‐1 : reactive center and amino‐terminal heterogeneity determined by protein and cDNA sequencing (1986) (201)
- Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. (1993) (201)
- Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptor (1991) (197)
- Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide (2005) (193)
- Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. (1991) (190)
- Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. (1995) (190)
- Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. (1994) (188)
- The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. (1998) (185)
- Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. (1989) (181)
- 92 kDa type IV collagenase (MMP‐9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer (1996) (179)
- Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. (1989) (177)
- Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. (1992) (174)
- immunocytochemical localization of urokinase-type plasminogen activator in lewis lung carcinoma (1984) (174)
- Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse (1984) (171)
- Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation (1991) (168)
- Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice (1998) (161)
- Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. (1991) (161)
- ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. (1997) (161)
- Reduced metastasis of transgenic mammary cancer in urokinase‐deficient mice (2005) (161)
- Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. (2001) (160)
- Human endothelial cells contain one type of plasminogen activator (1984) (158)
- The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. (1994) (157)
- uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion (2003) (156)
- The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. (1991) (155)
- The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. (1994) (153)
- The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction (1997) (146)
- Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. (2001) (142)
- The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. (1992) (141)
- Cross resistance between vinca alkaloids and anthracyclines in Ehrlich ascites tumor in vivo. (1972) (138)
- A Urokinase Receptor-associated Protein with Specific Collagen Binding Properties* (2000) (138)
- Plasminogen activation independent of uPA and tPA maintains wound healing in gene‐deficient mice (2006) (132)
- Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate (1989) (131)
- Cell-surface acceleration of urokinase-catalyzed receptor cleavage. (1997) (130)
- A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. (1993) (127)
- Lactational competence and involution of the mouse mammary gland require plasminogen. (2000) (125)
- Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. (1996) (122)
- Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. (1991) (121)
- Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. (1993) (119)
- Monoclonal Antibodies to Human 54,000 Molecular Weight Plasminogen Activator Inhibitor from Fibrosarcoma Cells - Inhibitor Neutralization and One-Step Affinity Purification (1986) (116)
- The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. (1995) (114)
- Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. (1994) (112)
- Urokinase‐receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells. (1991) (110)
- Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract (1991) (110)
- Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. (1995) (109)
- Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. (1993) (104)
- MMP-9 Is Differentially Expressed in Primary Human Colorectal Adenocarcinomas and Their Metastases (2006) (101)
- Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells. (1991) (101)
- Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. (1997) (100)
- Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus. (2005) (98)
- Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor (2007) (98)
- Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin. (1987) (97)
- A cleaved form of the receptor for urokinase‐type plasminogen activator in invasive transplanted human and murine tumors (1994) (97)
- The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria (1995) (94)
- Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization. (1991) (94)
- Domain Interplay in the Urokinase Receptor (1996) (93)
- uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV. (2004) (93)
- Serine enzymes released by cultured neoplastic cells (1978) (90)
- An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator (1993) (87)
- Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer (1998) (86)
- Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma (2003) (86)
- Urokinase Plasminogen Activator Is Localized in Stromal Cells in Ductal Breast Cancer (2001) (82)
- Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. (1991) (82)
- Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro. (1972) (81)
- Expression of urokinase plasminogen activator, its receptor and type‐1 inhibitor in malignant and benign prostate tissue (2005) (81)
- Stromal cell expression of components of matrix-degrading protease systems in human cancer. (1996) (80)
- Inactive proenzyme to tissue‐type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody. (1984) (79)
- Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation. (1993) (78)
- Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. (1988) (77)
- A functional overlap of plasminogen and MMPs regulates vascularization during placental development (2003) (73)
- A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. (1992) (72)
- Mapping Part of the Functional Epitope for Ligand Binding on the Receptor for Urokinase-type Plasminogen Activator by Site-directed Mutagenesis* (1999) (71)
- Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. (1997) (70)
- The plasminogen fibrinolytic pathway is required for hematopoietic regeneration. (2007) (69)
- Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice (2003) (69)
- lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. (1992) (69)
- Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. (1998) (68)
- Glycosylation Profile of a Recombinant Urokinase-type Plasminogen Activator Receptor Expressed in Chinese Hamster Ovary Cells* (1998) (66)
- Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. (2001) (66)
- Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. (2004) (63)
- Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor‐1 in colon cancer liver metastases (2009) (62)
- Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor. (2004) (62)
- The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene (1988) (62)
- The Urokinase Plasminogen Activator Receptor–Associated Protein/Endo180 Is Coexpressed with Its Interaction Partners Urokinase Plasminogen Activator Receptor and Matrix Metalloprotease-13 during Osteogenesis (2001) (62)
- Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites. (2004) (61)
- Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. (1992) (61)
- Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. (1994) (59)
- Urokinase receptor‐associated protein (UPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells (2002) (58)
- Plasminogen activator from cells transformed by an oncogenic virus: inhibitors of the activation reaction. (1979) (58)
- Plasminogen and wound healing (1996) (58)
- Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass (1986) (58)
- Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. (2000) (56)
- Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one‐step affinity purification. (1983) (56)
- Hormonal regulation of extracellular plasminogen activators and M r ∼ 54000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies (1986) (55)
- Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction. (1995) (54)
- Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion (1994) (54)
- Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. (2006) (53)
- Immunocytochemical demonstration of tissue-type plasminogen activator in endocrine cells of the rat pituitary gland (1985) (53)
- A precise and efficient stereological method for determining murine lung metastasis volumes. (2001) (52)
- A sensitive collagenase assay using [3H] collagen labeled by reaction with pyridoxal phosphate and [3H] borohydride. (1981) (51)
- Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer (2011) (51)
- Purification and characterization of a plasminogen activator from mouse cells transformed by an oncogenic virus. (1980) (51)
- Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q13.1-q13.2. (1992) (51)
- Inhibition of a plasminogen activator from oncogenic virus-transformed mouse cells by rabbit antibodies against the enzyme. (1980) (50)
- Development of resistance to daunomycin (NSC-82151) in Ehrlich ascites tumor. (1971) (50)
- Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells (1987) (50)
- Plasminogen activator inhibitor type 1: cell-specific and differentiation-induced expression and regulation in human cell lines, as determined by enzyme-linked immunosorbent assay (1988) (49)
- Urokinase-type plasminogen activator in endothelial cells during acute inflammation of the appendix. (1989) (49)
- Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. (2005) (48)
- Dynamics of urokinase receptor interaction with Peptide antagonists studied by amide hydrogen exchange and mass spectrometry. (2004) (48)
- Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy. (2001) (48)
- Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. (1994) (48)
- Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. (2005) (47)
- Proenzyme to urokinase‐type plasminogen activator in the mouse in vivo (1985) (45)
- Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme. (1982) (45)
- Co-ordinated expression of MMP-2 and its putative activator, MT1-MMP, in human placentation. (1997) (45)
- Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloids in vivo. A new treatment principle. (1984) (44)
- Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. (1997) (44)
- Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. (1993) (43)
- The urokinase receptor associated protein (uPARAP/endo180): a novel internalization receptor connected to the plasminogen activation system. (2001) (43)
- Development of resistance to adriamycin (NSC-123127) in Ehrlich ascites tumor in vivo. (1972) (43)
- Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1. (2004) (42)
- Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model (2008) (42)
- The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. (2000) (42)
- Immunohistochemical localization of urokinase-type plasminogen activator in Sertoli cells and tissue-type plasminogen activator in spermatogenic cells in the rat seminiferous epithelium. (1988) (41)
- Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies (1995) (40)
- Loss of ELISA specificity due to biotinylation of monoclonal antibodies. (2000) (39)
- Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology. (1999) (39)
- Urokinase-type plasminogen activator is increased in the involuting ventral prostate of castrated rats. (1990) (39)
- Plasminogen activating enzyme in cultured glioblastoma cells. An immunofluorescence study with monoclonal antibody. (1982) (39)
- The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. (2003) (39)
- The murine urokinase-type plasminogen activator receptor gene. (1994) (38)
- Cellular receptor for urokinase-type plasminogen activator: protein structure. (1993) (38)
- Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin. (2001) (37)
- Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. (2005) (36)
- Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis. (2010) (35)
- Plasminogen activator inhibitor type-1 protein, mRNA and gene transcription are increased by phorbol esters in human rhabdomyosarcoma cells. (1988) (35)
- Serologic factors in human transplantation. (1967) (35)
- Prognosis in adenocarcinomas of lower oesophagus, gastro‐oesophageal junction and cardia evaluated by uPAR‐immunohistochemistry (2012) (33)
- Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies. (1986) (32)
- Impaired migration in vitro of neutrophils from patients with paroxysmal nocturnal haemoglobinuria (1996) (31)
- Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer. (1994) (30)
- A Composite Role of Vitronectin and Urokinase in the Modulation of Cell Morphology upon Expression of the Urokinase Receptor* (2008) (28)
- crystal structure of urokinase plasminogen activator receptor (2005) (28)
- Diversity in catalytic properties of single chain and two chain tissue-type plasminogen activator (1991) (27)
- Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: Inhibitory effects on receptormediated uPA activity in vitro and in vivo (2007) (26)
- Tissue-type plasminogen activator in somatostatin cells of rat pancreas and hypothalamus. (1987) (25)
- Cellular receptor for urokinase-type plasminogen activator: function in cell-surface proteolysis. (1993) (24)
- Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane. (1994) (24)
- A novel, specific pro‐urokinase complex on monocyte‐like cells, detected by transglutaminase‐catalyzed cross‐linking (1993) (24)
- Generation of high-affinity rabbit polyclonal antibodies to the murine urokinase receptor using DNA immunization. (2000) (22)
- Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma (2004) (22)
- Experimentally developed cellular resistance to daunomycin. Resistance mechanisms, the daunomycin-pump and cross resistance to adriamycin, vincristine and vinblastine. (1976) (22)
- Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin. (1993) (20)
- Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI‐1) using random peptide phage‐display libraries (1998) (19)
- Localization of urokinase-type plasminogen activator receptor on U937 cells: phorbol ester PMA induces heterogeneity. (1990) (17)
- Tissue-type plasminogen activator in rat adrenal medulla (2004) (17)
- Effect of purified, soluble urokinase receptor on the plasminogen‐prourokinase activation system (1996) (17)
- ELISA for complexes between urokinase‐type plasminogen activator and its receptor in lung cancer tissue extracts (1997) (16)
- Domain Interplay in the Urokinase Receptor REQUIREMENT FOR THE THIRD DOMAIN IN HIGH AFFINITY LIGAND BINDING AND DEMONSTRATION OF LIGAND CONTACT SITES IN DISTINCT RECEPTOR DOMAINS* (1996) (16)
- The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. (1997) (16)
- The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene. (1988) (15)
- Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue (1993) (13)
- Mechanism of resistance to anthracyclines and vinca alkaloids. (1983) (13)
- Cell Surface Plasminogen Activation (1989) (12)
- The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin (2001) (12)
- Crohn's Disease But Not Chronic Ulcerative Colitis Induces the Expression of PAI-1 in Enteric Neurons (2008) (11)
- Okadaic acid strongly increases gene transcription, mRNA and protein level for the urokinase receptor in human A549 cells (1992) (10)
- Urokinase and urokinase receptor expression in somatic cell hybrids (1994) (10)
- Plasminogen activator inhibitors from placenta and fibrosarcoma cells are antigenically different as evaluated with monoclonal and polyclonal antibodies. (1987) (9)
- Urokinase-type receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies (1994) (8)
- Multidrug resistance: Drug extrusion and its counteraction by chemosensitizers (1989) (7)
- Karyotypic profile alterations in Ehrlich ascites tumour cells during development of resistance to daunorubicine. (2009) (6)
- Generation of Antibodies to the Urokinase Receptor (uPAR) by DNA Immunization of uPAR Knockout Mice: Membrane‐Bound uPAR is Not Required for an Antibody Response (2003) (6)
- A Key Molecule Dictating and Regulating Surface Plasmin Formation : The Receptor for Urokinase Plasminogen Activator (1990) (5)
- PLASMINOGEN ACTIVATOR INHIBITORS OF TYPE 1 (PAI-1) AND TYPE 2 (PAI-2) ARE PRESENT IN ASCITIC FLUID FROM PATIENTS WITH OVARIAN CARCINOMA (1987) (5)
- Reply to comment on ‘Effect of purified, soluble urokinase receptor on the plasminogen‐prourokinase activation system’ (A. A‐R. Higazi) (1997) (5)
- Plasminogen activation and cancer: Basic mechanisms and perspectives (2006) (4)
- General detection of proteins after electroblotting by trinitrobenzene sulphonic acid derivatization and immunochemical staining with a monoclonal antibody against the trinitrophenyl group. (1986) (4)
- Cross resistance and cellular uptake of 4′-O-methyldoxorubicin in experimental tumors with acquired resistance to doxorubicin (2004) (4)
- Cross-resistance between Adriamycin, Daunomycin and Vincristine in Ehrlich Ascites Tumor in vivo (1972) (4)
- Plasminogen activator inhibitor (type-1) in rat adrenal medulla (2004) (3)
- Expression of type IV collagenases in invasive tumors (1992) (3)
- Invasion and metastasis factors in breast cancer (1993) (3)
- Decreased drug uptake as a factor in cross-resistance between daunomycin, adriamycin and vincristine in ehrlich ascites tumor cells. Abstr. (1972) (3)
- [Rubidomycin-daunomycin therapy in acute myeloblastic leukemia]. (1968) (2)
- Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies. (1986) (2)
- Subcellular localization of urokinase-type plasminogen activator and its receptor on normal and PNH-affected neutrophils (1994) (1)
- 1491: Measurements of Urokinase Receptor Fractions and Human Glandular Kallikrein 2 in Serum Improves Discrimination of Men with Prostate Cancer from Men with no Evidence of Malignant Disease (2005) (1)
- 41 The intact urokinase receptor is required for high affinity vitronectin binding: Receptor cleavage prevents ligand interaction (1997) (1)
- Characteristics of plasminogen activation by glycosylphosphatidylinositol- and transmembrane-anchored uPA (1994) (1)
- 116 Elisa determination of the complex between urokinase plasminogen activator and its type-1 inhibitor in tumor extracts (1997) (1)
- 39 A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor (2008) (1)
- Niels Behrendt , Ebbe Rønne and Keld Danø LIGAND CONTACT SITES IN DISTINCT RECEPTOR DOMAINS DOMAIN IN HIGH AFFINITY LIGAND BINDING AND DEMONSTRATION OF Domain Interplay in the Urokinase Receptor : REQUIREMENT FOR THE THIRD (1996) (1)
- 232 Purification and partial characterization of the cellular receptor for urokinase-type plasminogen activator (1988) (1)
- 44 The receptor for urokinase type plasminogen activator is deposited on the substratum by both normal and tumorderived human cells in culture: Studies by fluorescence and photoelectron microscopy (1997) (1)
- Urokinase-type plasminogen activator in plasma from breast cancer patients (1988) (1)
- Structural analysis of the interaction between urokinase and its receptor - a potential target for anti-invasive cancer therapy (2002) (1)
- [Biochemical mechanism for extracellular proteolysis. Tissue destruction and cancer]. (1983) (1)
- Inactive zymogen forms of plasminogen activators from human neoplastic cells (1983) (1)
- [New principles of treatment in acute leukemia]. (1970) (1)
- [Carcinogenesis and drugs]. (1981) (1)
- 144 PROGNOSTIC IMPACT OF U-PAR IN METASTATIC PROSTATE CANCER (2010) (1)
- Localization of components from the plasminogen activation system in normal and tumor tissue using in situ hybridization and immunohistochemistry (1989) (0)
- SENSITIVE AND SPECIFIC ENZYME-LINKED IMMUNOSORBENT ASSAY FOR UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN HUMAN PLASMA (1987) (0)
- 1812: Enhanced Discrimination of Benign from Malignant Prostatic Disease by Novel Measurements of Cleaved Urokinase Receptor forms in Serum (2004) (0)
- 754 Role of plasminogen activation system (2003) (0)
- Transforming growth factor-beta induces incresed level of plasminogen activator inhibitor mRNA in human lung fibroblasts (1987) (0)
- 104 Urokinase receptor in serum of ovarian cancer patients (1997) (0)
- 194 Subcellular distribution of urokinase-type plasminogen activator and uPA-receptor in neutrophils determined by immunogold labeling and electron microscopy (1997) (0)
- Mapping of PAI-1 to a region of abnormalities of chromosome 7 in cancer (1987) (0)
- Stromal cell involvement and functional overlap in extracellular proteolysis in cancer invasion and non-neoplastic tissue remodeling (1998) (0)
- uPA binding site on 2 + 3 domain of uPAR and reacting antibodies (1995) (0)
- [Resistance development under cytostatic treatment]. (1971) (0)
- Regulation of type-1 plasminogen activator inhibitor (PAI-1) gene expression in human cell lines (1989) (0)
- Demonstration of the cellular receptor for urokinase-type plasminogen activator in human chorion (1989) (0)
- 82 Reduced breast cancer metastasis in plasminogen-deficient mice (1997) (0)
- Novel Functions for a Fibrinolytic Pathway in Controlling the Stem Cell Niche. (2006) (0)
- Gene Expression and Function of the Cellular Receptor for u-PA (u-PAR) (2019) (0)
- Mechanism of decreased accumulation of daunomycin in resistant ehrlich ascites tumor cells. Abstr. (1973) (0)
- [Basic cancer biology]. (1989) (0)
- 34 Identification of a novel membrane protein that interacts specifically with the uPAR-prourokinase complex (1997) (0)
- Urokinase-type plasminogen activator is increased during castration-induced involution of the rat ventral prostate (1989) (0)
- Tumor necrosis factor-alpha regulates urokinase-type plasminogen activator and its type-1 inhibitor in human neoplas71c cell lines (1989) (0)
- The phorbol ester, PMA, increases cellular levels of mRNA coding for plasminogen activator inhibitor type-1 (PAI-1) in human neoplastic cells (1988) (0)
- [Use of chemotherapy in combination with surgery and irradiation in cases of nephroblastoma (Wilm's tumor)]. (1973) (0)
- 257 Pro-u-PA activation. A crucial step in regulation of pericellular proteolysis during cell migration? (1988) (0)
- 42 Type-1 plasminogen activator inhibitor (PAI-1): Cell-specific expression and hormonal regulation in human cell lines (1988) (0)
- 188 Establishment of murine monoclonal antibodies against murine urokinase receptor raised in urokinase receptor knock-out mice (1997) (0)
- 89 Histochemical studies of matrix degrading proteases in human breast cancer (1997) (0)
- PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1: STUDIES ON STRUCTURE AND REGULATION (1987) (0)
- SINGLE-CHAIN UROKINASE TYPE PLASMINOGEN ACTIVATOR (SCU-PA) FROM HT-1080 HUMAN FIBROSARCOMA CELLS IS A GENUINE PROENZYME (1987) (0)
- 99 High preoperative blood levels of urokinase plasminogen activator receptor (UPAR) and carcinoembryonic antigen (CEA) defines a group of colorectal cancer patients with poor prognosis (1997) (0)
- 169 Mutational analysis of binding determinants in the human receptor for urokinase-type plasminogen activator (1997) (0)
- Messenger RNA for urokinase Plasminogen Activator (uPA) in benign and malignant human breast lesions. An in situ hybridization study (1994) (0)
- Plasminogen activator receptor-urokinase (1990) (0)
- Urokinase-type plasminogen activator and its receptor: Involvement of stromal cells in generation of proteolytic activity during cancer invasion (1994) (0)
- 106 Association of preoperative plasma PAI-1 and CRP levels in patients with colorectal cancer (1997) (0)
- [New basis for development of anticancer drugs]. (2001) (0)
- 84 Role of matrix degrading proteinases in wound healing and skin cancer (1997) (0)
- 316 Increased production of plasminogen activator inhibitor type-1 (PAI-1) in human neoplastic cell lines exposed to tumor-promoting phorbol esters (1988) (0)
- A composite role of vitronectin and uPAR in cell morphology (2008) (0)
- 83 Stromal cell involvement and functional overlap in extracellular proteolysis in cancer invasion and non-neoplastic tissue remodeling (1997) (0)
- Tumor necrosis factor α regulates components of the plasminogen activation system in human neoplastic cell lines (1988) (0)
- Transforming growth factor-β and glucocorticoid regulation of plasminogen activator inhibitor type-1 (1987) (0)
- Molecular studies of the cellular receptor for urokinase-type plasminogen activator (1988) (0)
- ID: 257 Cleavage of uPAR; mechanism and prognostic significance. (2006) (0)
- 165 Ligand binding determinants within the receptor for urokinase-type plasminogen activator as delineated by photolabelling and site-directed mutagenesis (1997) (0)
- ID: 262 Inhibition of mouse uPA activity by mouse monoclonal antibodies (2006) (0)
- [Organization of theoretical postgraduate medical training]. (1971) (0)
- Co-localization of plasminogen activator inhibit-or type-1 and tissue-type plasminogen activator in endocrine cells of the rat adrenal medulla (1989) (0)
- ID: 261 Generation and characterization of murine monoclonal antibodies against murine uPAR (2006) (0)
- 102 Urokinase plasminogen activator receptor in plasma is an independent prognostic variable in patients with colorectal cancer (1997) (0)
- 310 Localisation of plasminogen activators and plasminogen activator inhibitor (Type 1) in normal and neoplastic tissue (1988) (0)
- [Rubidomycin-daunomycin, a new antibiotic with antineoplastic effect]. (1968) (0)
- Activation of receptor bound pro-uroignase may be a crucial regulatory step in cell-surface plasminogen activation (1989) (0)
- 3 The Expression Pattern of the Urokinase Plasminogen Activation System in Human Colon Cancer Is Recapitulated in Liver Metastases with Desmoplastic Encapsulation (2008) (0)
- Interaction between receptor-bound uPA and its inhibitor type-1 (PAI-1) in human U937 cells (1989) (0)
- Type-1 plasminogen activator inhibitor (PAI-1): Cell-specific expression and hormonal regulation in human cell lines (1988) (0)
- 68 Impairment of post-lactational involution of the mammary gland in mice deficient for the plasminogen gene (1997) (0)
- Profiling changes in keratinocyte gene expression during wound reepithelialization by laser capture microdissection combined with cDNA array analysis (2001) (0)
- 175 Different mechanisms are involved in the antibody mediated inhibition of the interaction between the urokinase-type plasminogen activator and its receptor (1997) (0)
- Award Number: W81XWH-05-1-0272 TITLE: Biological Function of Plasma Kallikrein in Mammary Gland Stromal Development and Tumor Metastasis (2006) (0)
- Abstract 2342: Prognosis for patients with adenocarcinomas of lower esophagus, gastro-esophageal junction and cardia can be directly evaluated by immunohistochemistry of uPAR (2010) (0)
- The receptor for urokinase plasminogen activator is resent in both the ligand-binding and the cleaved form in ductal breast carcinoma (1994) (0)
- Pathophysiology of cellular fibrinolysis (1994) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Keld Danø?
Keld Danø is affiliated with the following schools:
